To date, one isolated study has reported the anti-cancer properties of RNAi-mediated GHR silencing in cultured human pancreatic cancer cells [41], and no studies have reported the in vivo use of GHR antagonism or a combination of GHRAs with commonly used chemotherapies to improve therapeutic outcomes in any cancer. The gene discussed is GHR; the disease is pancreatic neoplasm.